PDS Biotechnology Corporation
Price Action
Technical Summary
CONSOLIDATINGPDS Biotechnology Corporation is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 58), indicating performance broadly in line with the market. Earnings growth of 38% provides fundamental context to the price action. Investors should exercise caution due to high volatility (99% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.02 | -12.59% | BELOW |
| 50 SMA | $1.09 | -18.46% | BELOW |
| 100 SMA | $0.91 | -1.82% | BELOW |
| 150 SMA | $0.90 | -1.12% | BELOW |
| 200 SMA | $0.92 | -3.55% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PDSB in an uptrend right now?
PDSB has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is PDSB overbought or oversold?
PDSB's RSI (14) is 41. The stock is in neutral territory, neither overbought nor oversold.
Is PDSB outperforming the market?
PDSB has a Relative Strength (RS) Rating of 58 out of 99. PDSB is performing about average compared to the market.
Where is PDSB in its 52-week range?
PDSB is trading at $0.89, which is 57% of its 52-week high ($1.55) and 36% above its 52-week low ($0.52).
How volatile is PDSB?
PDSB has a Beta of 3.03 and 52-week volatility of 99%. It's more volatile than the S&P 500 - expect bigger swings.